Data / Drug companies / Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc.
Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc.: 274 products in the FDA NDC directory, labeler code 23155
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. (labeler code 23155) lists 274 products in the FDA National Drug Code Directory, covering 110 finished drugs by generic name. By type: 274 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 7, 2026.
The request: Watch Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. (FDA labeler code 23155): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 23155
- Products in commercial distribution
- 274
- Packages
- 509
- Finished drugs by generic name
- 110
- Prescription products
- 274
- Over the counter products
- 0
- Controlled substance products
- Schedule III 1, Schedule IV 6
- Flagged as original packager
- 259 of 259 products that carry the flag
- Started marketing in the last 12 months
- 27
- Products with a marketing end date set
- 24
- Earliest marketing start
- October 29, 2009
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 270 | 98.5% |
| Authorized generics (NDA) | 2 | 0.7% |
| New drug applications (NDA) | 2 | 0.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 274 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 117 | 42.7% |
| Capsule | 48 | 17.5% |
| Injection, solution | 28 | 10.2% |
| Injection | 22 | 8% |
| Tablet, film coated | 16 | 5.8% |
| Capsule, liquid filled | 7 | 2.6% |
| Tablet, extended release | 5 | 1.8% |
| Powder, for solution | 5 | 1.8% |
| Injection, powder, lyophilized, for solution | 4 | 1.5% |
| Tablet, delayed release | 4 | 1.5% |
| Kit | 3 | 1.1% |
| Tablet, film coated, extended release | 3 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Fluorouracil | 23155-975 | Injection, solution | Generic drugs (ANDA) | September 7, 2026 |
| Fluorouracil | 23155-974 | Injection, solution | Generic drugs (ANDA) | September 7, 2026 |
| Fluorouracil | 23155-973 | Injection, solution | Generic drugs (ANDA) | September 7, 2026 |
| Fluorouracil | 23155-972 | Injection, solution | Generic drugs (ANDA) | September 7, 2026 |
| Vancomycin hydrochloride | 23155-968 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Vancomycin hydrochloride | 23155-967 | Capsule | Generic drugs (ANDA) | August 10, 2026 |
| Nisoldipine | 23155-977 | Tablet, film coated, extended release | Generic drugs (ANDA) | August 1, 2026 |
| Nisoldipine | 23155-976 | Tablet, film coated, extended release | Generic drugs (ANDA) | August 1, 2026 |
| Amlodipine and Benazepril Hydrochloride | 23155-924 | Capsule | Generic drugs (ANDA) | July 24, 2026 |
| Amlodipine and Benazepril Hydrochloride | 23155-923 | Capsule | Generic drugs (ANDA) | July 24, 2026 |
| Meclizine hydrochloride | 23155-943 | Tablet | Generic drugs (ANDA) | June 25, 2026 |
| Benzphetamine Hydrochloride | 23155-952 | Tablet, film coated | Generic drugs (ANDA) | June 19, 2026 |
| Oxybutynin Chloride | 23155-913 | Tablet | Generic drugs (ANDA) | June 1, 2026 |
| Amlodipine and Benazepril Hydrochloride | 23155-921 | Capsule | Generic drugs (ANDA) | May 23, 2026 |
| Labetalol Hydrochloride | 23155-726 | Tablet | Generic drugs (ANDA) | May 15, 2026 |
| Midodrine Hydrochloride | 23155-971 | Tablet | Generic drugs (ANDA) | March 25, 2026 |
| Midodrine Hydrochloride | 23155-970 | Tablet | Generic drugs (ANDA) | March 25, 2026 |
| Midodrine Hydrochloride | 23155-969 | Tablet | Generic drugs (ANDA) | March 25, 2026 |
| Celecoxib | 23155-966 | Capsule | Generic drugs (ANDA) | March 25, 2026 |
| Celecoxib | 23155-965 | Capsule | Generic drugs (ANDA) | March 25, 2026 |
| Celecoxib | 23155-964 | Capsule | Generic drugs (ANDA) | March 25, 2026 |
| Celecoxib | 23155-963 | Capsule | Generic drugs (ANDA) | March 25, 2026 |
| Acyclovir | 23155-962 | Capsule | Generic drugs (ANDA) | March 25, 2026 |
| Amlodipine and Benazepril Hydrochloride | 23155-922 | Capsule | Generic drugs (ANDA) | January 21, 2026 |
| Amlodipine and Benazepril Hydrochloride | 23155-920 | Capsule | Generic drugs (ANDA) | December 19, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.